Clinical Trials
Below are current clinical trials.
155 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Scottsdale/Phoenix, Ariz.
This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who have failed prior therapy with pegylated interferon and RBV. The primary study hypothesis is that in at least one of the study arms, the percentage of participants achieving sustained viral response 12 weeks after the end of all study treatment (SVR12) will be superior to 58%.
-
Rochester, Minn.
The purpose of this study is to provide the lab with a source of human PBMCs and serum from normal and HIV-1-infected individuals. We wish to analyze cells from HIV-infected and non-HIV infected individuals for levels of various proteins and mRNAs that are relevant to HIV research.
-
Rochester, Minn.
The DRCFI treatment will influence the time to first pulmonary exacerbation compared to placebo.
-
Scottsdale/Phoenix, Ariz.
The purpose of this open-label extension of CDI-001 (subsequently referred to as PRISM 3) is to evaluate the safety and efficacy in reducing recurrence of CDI in adults who had a recurrence within 8 weeks of receiving CP101 or placebo in PRISM 3. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be eligible to be enrolled in the extension study and administered CP101. Approximately 70 subjects will receive CP101. The treatment duration will be 1 day. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following receipt of CP101. The primary efficacy and safety endpoints will be evaluated at 8 weeks post treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI.
-
Rochester, Minn.
The purpose of the study is to determine the extent of donor site morbidity after harvesting the medial femoral condyle for scaphoid nonunion treatment. The outcomes being measured are: superficial infection, deep infection, pain (short term), pain (long term), knee function and quality of scar.
-
Rochester, Minn.
The purpose of this study is to support the use of fingerstick whole blood on the Chembio DPP® Zika IgM Assay System.
-
Rochester, Minn.
The purpose of this study is to see how effective a new technology called the electronic nose is in identifying specific infection (C. difficile) from stool samples, by analyzing the gasses the stool gives off.
-
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to determine the safety, toxicity and maximum tolerated dose (MTD) / maximum feasible dose (MFD) of Ad/MG1-E6E7, and sequential treatment with atezolizumab in patients with HPV associated cancers.
-
Scottsdale/Phoenix, Ariz., Rochester, Minn.
The purpose of this study is to evaluate clinical experience with donor screening for fecal transplant, and to evaluate the outcomes from fecal transplant and understand risk factors for fecal transplant failure and relapse after fecal transplant.
-
Rochester, Minn., Jacksonville, Fla.
The purpose of this study is to evaluate the effectiveness of Vacuum-assisted dressings for treating patients who have open chest wounds by comparing the time-to-closure of such wounds to traditional wound care management.